| 1 |
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study [J]. Circulation, 2014, 129(8): 837-847.
|
| 2 |
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study [J]. JAMA, 2001, 285(18): 2370-2375.
|
| 3 |
Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study [J]. Circulation, 2004, 110(9): 1042-1046.
|
| 4 |
李焰生. 心房颤动患者的卒中预防进展与挑战 [J/CD]. 中华脑血管病杂志(电子版), 2012, 6(1): 1-4.
|
| 5 |
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur Heart J, 2016, 37(38): 2893-2962.
|
| 6 |
Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management [J]. Circ J, 2015, 79(3): 495-502.
|
| 7 |
李延广, 祖凌云, 刘书旺. 新发心房颤动风险评估的研究进展 [J/OL]. 中华脑血管病杂志(电子版), 2020, 14(3): 133-139.
|
| 8 |
Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation [J]. Nat Rev Cardiol, 2015, 12(4): 230-243.
|
| 9 |
Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation [J]. Eur Heart J, 2005, 26(20): 2083-2092.
|
| 10 |
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity [J]. Annu Rev Immunol, 2011, 29: 415-445.
|
| 11 |
Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension [J]. Hypertension, 2011, 57(2): 132-140.
|
| 12 |
Marzilli M, Merz CN, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! [J]. J Am Coll Cardiol, 2012, 60(11): 951-956.
|
| 13 |
Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation [J]. BMC Cardiovasc Disord, 2011, 11: 77.
|
| 14 |
Saba S, Janczewski AM, Baker LC, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-alpha [J]. Am J Physiol Heart Circ Physiol, 2005, 289(4): H1456-H1467.
|
| 15 |
Sawaya SE, Rajawat YS, Rami TG, et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor [J]. Am J Physiol Heart Circ Physiol, 2007, 292(3): H1561-H1567.
|
| 16 |
Lee SH, Chen YC, Chen YJ, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes [J]. Life Sci, 2007, 80(19): 1806-1815.
|
| 17 |
Kao YH, Chen YC, Cheng CC, et al. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes [J]. Crit Care Med, 2010, 38(1): 217-222.
|
| 18 |
Liu Z, Finet JE, Wolfram JA, et al. Calcium/calmodulin-dependent protein kinase Ⅱ causes atrial structural remodeling associated with atrial fibrillation and heart failure [J]. Heart Rhythm, 2019, 16(7): 1080-1088.
|
| 19 |
Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation [J]. Nat Med, 2010, 16(4): 470-474.
|
| 20 |
Burstein B, Libby E, Calderone A, et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences [J]. Circulation, 2008, 117(13): 1630-1641.
|
| 21 |
Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation [J]. J Clin Invest, 2011, 121(8): 2955-2968.
|
| 22 |
Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation [J]. J Am Coll Cardiol, 2012, 60(22): 2263-2270.
|
| 23 |
Patel P, Dokainish H, Tsai P, et al. Update on the association of inflammation and atrial fibrillation [J]. J Cardiovasc Electrophysiol, 2010, 21(9): 1064-1070.
|
| 24 |
You L, Wang P, Lv J, et al. The role of high-sensitivity C-reactive protein, interleukin-6 and cystatin C in ischemic stroke complicating atrial fibrillation [J]. J Huazhong Univ Sci Technolog Med Sci, 2010, 30(5): 648-651.
|
| 25 |
邱晓雪, 李世文, 于鹭, 等. 炎症反应与缺血性卒中 [J]. 中国卒中杂志, 2020, 15(1): 108-114.
|
| 26 |
Lin YJ, Tsao HM, Chang SL, et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation [J]. Am J Cardiol, 2010, 105(4): 495-501.
|
| 27 |
Conway DS, Buggins P, Hughes E, et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation [J]. Am Heart J, 2004, 148(3): 462-466.
|
| 28 |
Kim S, Eliot M, Koestler DC, et al. Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the jackson heart study and modification by the duffy antigen variant [J]. JAMA Cardiol, 2018, 3(6): 455-462.
|
| 29 |
Bass DA, Parce JW, Dechatelet LR, et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation [J]. J Immunol, 1983, 130(4): 1910-1917.
|
| 30 |
Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction [J]. N Engl J Med, 1974, 290(23): 1275-1278.
|
| 31 |
Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? [J]. J Am Coll Cardiol, 2005, 45(10): 1638-1643.
|
| 32 |
Chatterjee S, Chandra P, Guha G, et al. Pre-procedural elevated white blood cell count and neutrophil-lymphocyte (N/L) ratio are predictors of ventricular arrhythmias during percutaneous coronary intervention [J]. Cardiovasc Hematol Disord Drug Targets, 2011, 11(2): 58-60.
|
| 33 |
Adamstein NH, Macfadyen JG, Rose LM, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials [J]. Eur Heart J, 2021, 42(9): 896-903.
|
| 34 |
Karavelioglu Y, Karapinar H, Yuksel M, et al. Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone [J]. Clin Appl Thromb Hemost, 2015, 21(1): 5-9.
|
| 35 |
Arıbaş A, Akilli H, Gul EE, et al. Can neutrophil/lymphocyte ratio predict recurrence of non-valvular atrial fibrillation after cardioversion? [J]. Anadolu Kardiyol Derg, 2013, 13(2): 123-130.
|
| 36 |
Schmidt B, Brugada J, Arbelo E, et al. Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA atrial fibrillation ablation long-term registry [J]. Europace, 2020, 22(4): 558-566.
|
| 37 |
Pallisgaard JL, Gislason GH, Hansen J, et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study [J]. Eur Heart J, 2018, 39(6): 442-449.
|
| 38 |
Kornej J, Schumacher K, Sommer P, et al. Very late arrhythmia recurrences in patients with sinus rhythm within the first year after catheter ablation: the leipzig heart center AF ablation registry [J]. Europace, 2019, 21(11): 1646-1652.
|
| 39 |
Koroglu S, Tuncer C, Acar G, et al. Relation of inflammatory and oxidative markers to the occurrence and recurrence of persistent atrial fibrillation [J]. Turk Kardiyol Dern Ars, 2012, 40(6): 499-504.
|
| 40 |
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study [J]. JAMA, 2014, 311(5): 498-506.
|
| 41 |
Canpolat U, Aytemir K, Yorgun H, et al. Role of preablation neutrophil/lymphocyte ratio on outcomes of cryoballoon-based atrial fibrillation ablation [J]. Am J Cardiol, 2013, 112(4): 513-519.
|
| 42 |
Im SI, Shin SY, Na JO, et al. Usefulness of neutrophil/lymphocyte ratio in predicting early recurrence after radiofrequency catheter ablation in patients with atrial fibrillation [J]. Int J Cardiol, 2013, 168(4): 4398-4400.
|
| 43 |
Guo X, Zhang S, Yan X, et al. Postablation neutrophil/lymphocyte ratio correlates with arrhythmia recurrence after catheter ablation of lone atrial fibrillation [J]. Chin Med J (Engl), 2014, 127(6): 1033-1038.
|
| 44 |
Yano M, Egami Y, Ukita K, et al. Atrial fibrillation type modulates the clinical predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation recurrence after catheter ablation [J]. Int J Cardiol Heart Vasc, 2020, 31100664.
|
| 45 |
Gibson PH, Cuthbertson BH, Croal BL, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting [J]. Am J Cardiol, 2010, 105(2): 186-191.
|
| 46 |
Erdem K, Ayhan S, Ozturk S, et al. Usefulness of the mean platelet volume for predicting new-onset atrial fibrillation after isolated coronary artery bypass grafting [J]. Platelets, 2014, 25(1): 23-26.
|
| 47 |
Durukan AB, Gurbuz HA, Unal EU, et al. Role of neutrophil/lymphocyte ratio in assessing the risk of postoperative atrial fibrillation [J]. J Cardiovasc Surg (Torino), 2014, 55(2): 287-293.
|
| 48 |
Chavarria N, Wong C, Hussain H, et al. Persistent elevation of neutrophil/lymphocyte ratio associated with new onset atrial fibrillation following percutaneous coronary intervention for acute ST segment elevation myocardial infarction [J]. J Ayub Med Coll Abbottabad, 2015, 27(2): 441-447.
|
| 49 |
Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation [J]. J Arrhythm, 2017, 33(4): 345-367.
|
| 50 |
Yalcin M, Aparci M, Uz O, et al. Neutrophil-lymphocyte ratio may predict left atrial thrombus in patients with nonvalvular atrial fibrillation [J]. Clin Appl Thromb Hemost, 2015, 21(2): 166-171.
|
| 51 |
Fukuda Y, Okamoto M, Tomomori S, et al. In paroxysmal atrial fibrillation patients, the neutrophil-to-lymphocyte ratio is related to thrombogenesis and more closely associated with left atrial appendage contraction than with the left atrial body function [J]. Intern Med, 2018, 57(5): 633-640.
|
| 52 |
Fang YN, Tong MS, Sung PH, et al. Higher neutrophil counts and neutrophil-to-lymphocyte ratio predict prognostic outcomes in patients after non-atrial fibrillation-caused ischemic stroke [J]. Biomed J, 2017, 40(3): 154-162.
|
| 53 |
Saliba W, Barnett-Griness O, Elias M, et al. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study [J]. J Thromb Haemost, 2015, 13(11): 1971-1979.
|
| 54 |
Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review [J]. Expert Rev Cardiovasc Ther, 2013, 11(1): 55-59.
|